| 2026-03-11 |
详情>>
内部人交易：
Knight Lea Daniels等共交易2笔
|
| 2026-02-26 |
详情>>
股本变动：
变动后总股本7793.72万股
|
| 2026-02-26 |
详情>>
业绩披露：
2025年年报每股收益-6.74美元,归母净利润-5.16亿美元,同比去年增长-7337.7%
|
| 2026-02-26 |
财报披露：
美东时间 2026-02-26 盘前发布财报
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-6.72美元,归母净利润-5.15亿美元,同比去年增长-1851.44%
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益-6.65美元,归母净利润-5.09亿美元,同比去年增长-3147.89%
|
| 2025-05-05 |
详情>>
业绩披露：
2025年一季报每股收益-0.33美元,归母净利润-2529.3万美元,同比去年增长-670.89%
|
| 2025-04-04 |
股东大会：
将于2025-05-09召开股东大会
会议内容 ▼▲
- 1.To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2025.
3.To approve, on an advisory basis, the compensation of our named executive officers.
4.To approve Amendment No. 2 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan.
|
| 2025-02-25 |
详情>>
业绩披露：
2024年年报每股收益-0.09美元,归母净利润-694.4万美元,同比去年增长-110.25%
|
| 2025-02-25 |
详情>>
业绩披露：
2022年年报每股收益2.18美元,归母净利润1.81亿美元,同比去年增长6.79%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.34美元,归母净利润-2637.9万美元,同比去年增长-155.06%
|
| 2024-11-04 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.59美元,归母净利润4790.70万美元,同比去年增长-62.46%
|
| 2024-07-29 |
详情>>
业绩披露：
2024年中报每股收益-0.2美元,归母净利润-1568.3万美元,同比去年增长-155.2%
|
| 2024-05-06 |
复牌提示：
2024-05-06 09:32:22 停牌，复牌日期 2024-05-06 09:37:22
|
| 2024-05-06 |
详情>>
业绩披露：
2024年一季报每股收益-0.04美元,归母净利润-328.1万美元,同比去年增长-113.54%
|
| 2024-04-04 |
股东大会：
将于2024-05-09召开股东大会
会议内容 ▼▲
- 1.To elect nine directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2024.
3.To approve, on an advisory basis, the compensation of our named executive officers.
4.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Company Charter”) to reflect new Delaware Law provisions regarding officer exculpation.
5.To approve Amendment No. 1 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益0.85美元,归母净利润6774.10万美元,同比去年增长-62.48%
|
| 2023-04-06 |
股东大会：
将于2023-05-12召开股东大会
会议内容 ▼▲
- 1.To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2023.
3.To approve, on an advisory basis, the compensation of our named executive officers.
4.To approve, on an advisory basis, the frequency of the advisory approval of the compensation of our named executive officers.
|
| 2022-04-08 |
股东大会：
将于2022-05-13召开股东大会
会议内容 ▼▲
- 1.To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2022.
3.To vote on a non-binding resolution to approve the compensation of our named executive officers.
4.To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-09 |
股东大会：
将于2021-05-14召开股东大会
会议内容 ▼▲
- 1.To elect nine directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2021.
3.To approve the Fifth Amended and Restated 2003 Equity Incentive Plan.
4.To vote on a non-binding resolution to approve the compensation of our named executive officers.
5.To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|
| 2020-04-08 |
股东大会：
将于2020-05-13召开股东大会
会议内容 ▼▲
- 1.To elect nine directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2020.
3.To vote on a non-binding resolution to approve the compensation of our named executive officers.
4.To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|
| 2019-04-16 |
股东大会：
将于2019-05-16召开股东大会
会议内容 ▼▲
- 1.To elect nine directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2019.
3.To vote on a non-binding resolution to approve the compensation of our named executive officers.
4.To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|
| 2018-04-06 |
股东大会：
将于2018-05-17召开股东大会
会议内容 ▼▲
- 1. To elect nine directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2018.
3. To vote on a non-binding resolution to approve the compensation of our named executive officers.
4. To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|
| 2017-04-17 |
股东大会：
将于2017-05-23召开股东大会
会议内容 ▼▲
- 1.To elect nine directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2017.
3.To approve the Company’s 2018 Performance Incentive Compensation Plan.
4.To approve the Company’s Fourth Amended and Restated 2003 Equity Incentive Plan.
5.To vote on a non-binding resolution to approve the compensation of our named executive officers.
6.To vote on a non-binding Proposal on the frequency of the advisory vote on the compensation of our named executive officers.
7.To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|
| 2016-11-07 |
股东大会：
将于2016-12-21召开股东大会
会议内容 ▼▲
- 1. To vote upon a proposal to amend the Company’s Amended and Restated Certificate of Incorporation, as amended to increase the number of authorized shares of common stock of the Company (“Common Stock”) from 60,000,000 to 240,000,000 shares (the “Amendment”) for the purpose of, among other things, effecting a proposed two-for-one stock split of the Company’s Common Stock as part of the Amendment.
2. To act upon any other matters properly coming before the Special Meeting or any adjournment or postponement thereof.
|
| 2016-10-27 |
详情>>
拆分方案：
每1.0000股拆分成2.0000股
|
| 2016-04-15 |
股东大会：
将于2016-05-24召开股东大会
会议内容 ▼▲
- 1. To elect ten directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year 2016.
3. To vote on a non-binding resolution to approve the compensation of our named executive officers.
4. To act upon any other matters properly coming before the Meeting or any adjournment or postponement thereof.
|